Related Experiment Videos
Localized lepromatous leprosy and its response to chemo-immunotherapy
K R Beena1, S A Zaheer, I Guleria
1National Institute of Immunology, New Delhi, India.
International Journal of Dermatology
|January 1, 1994
Summary
Chemo-immunotherapy with Mycobacterium w vaccine significantly improved lepromatous leprosy (LL) in a young boy. Treatment led to bacterial clearance, lepromin conversion, and histological upgrading, demonstrating vaccine efficacy.
Area of Science:
- Immunology
- Dermatology
- Infectious Diseases
Background:
- Leprosy diagnosis and classification can be challenging, especially in young patients.
- Lepromatous leprosy (LL) is a severe form of the disease.
- Leprosy immunotherapy trials are crucial for developing new treatment strategies.
Observation:
- A 12-year-old boy presented with an unusual localized form of lepromatous leprosy.
- Initial diagnosis was borderline tuberculoid leprosy, later confirmed as LL with a high bacterial index (BI).
- The patient received chemo-immunotherapy, including standard multidrug therapy and a Mycobacterium w (M.w) antileprosy vaccine.
Findings:
- After 15 months of treatment, the patient showed a dramatic reduction in bacterial load (BI from 6+ to 0).
- The patient converted from negative to positive on the lepromin test (5 mm).
- Histopathological examination revealed upgrading from lepromatous leprosy to borderline tuberculoid, with favorable immunological responses (IL-2, IFN-gamma).
Implications:
- This case highlights the potential of chemo-immunotherapy with M.w vaccine in treating LL.
- Accurate diagnosis using slit-skin smears and biopsy is critical for effective leprosy management.
- The observed histological upgrading suggests a robust immune response induced by the vaccine.